Literature DB >> 6667903

Molar antithrombin concentration in normal human plasma.

J Conard, F Brosstad, M Lie Larsen, M Samama, U Abildgaard.   

Abstract

Crude, commercial thrombin preparations and purified bovine thrombin were incubated with normal human reference plasma and the amount of thrombin inactivated was calculated. 1 ml of human plasma inactivated 140-193 NIH U of the various crude thrombin preparations. In the presence of heparin, a lower thrombin-inactivating capacity of plasma was confirmed using crude thrombin, but this phenomenon was less pronounced with the purified thrombin preparation. The molar concentration of the purified bovine thrombin was determined by active site titration. Comparing with protein concentration (A280), this preparation was 92% pure. 1 ml of human plasma inactivated 2.57 mumol of thrombin in the absence of heparin, and 2.50 mumol with heparin. Assuming 1:1 stoichiometry in the thrombin-antithrombin reaction, these results suggest that the concentration of antithrombin in the pooled reference plasma is approximately 2.57 mumol/l or 0.15 g/l.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6667903     DOI: 10.1159/000214823

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  21 in total

1.  Specificity of binding of the low density lipoprotein receptor-related protein to different conformational states of the clade E serpins plasminogen activator inhibitor-1 and proteinase nexin-1.

Authors:  Jan K Jensen; Klavs Dolmer; Peter G W Gettins
Journal:  J Biol Chem       Date:  2009-05-13       Impact factor: 5.157

2.  Development and evaluation of a prototype of a novel clotting time test to monitor enoxaparin.

Authors:  Abhishek Gulati; James M Faed; Geoffrey K Isbister; Stephen B Duffull
Journal:  Pharm Res       Date:  2011-08-06       Impact factor: 4.200

3.  A rapid pro-hemostatic approach to overcome direct oral anticoagulants.

Authors:  Nabil K Thalji; Lacramioara Ivanciu; Robert Davidson; Phyllis A Gimotty; Sriram Krishnaswamy; Rodney M Camire
Journal:  Nat Med       Date:  2016-07-25       Impact factor: 53.440

Review 4.  Revisiting the Pharmacology of Unfractionated Heparin.

Authors:  Abdallah Derbalah; Stephen Duffull; Fiona Newall; Katie Moynihan; Hesham Al-Sallami
Journal:  Clin Pharmacokinet       Date:  2019-08       Impact factor: 6.447

5.  Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins.

Authors:  Francis Paolucci; Marie-Christine Claviés; François Donat; José Necciari
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

6.  Strategy for degradomic-peptidomic analysis of human blood plasma.

Authors:  Yufeng Shen; Tao Liu; Nikola Tolić; Brianne O Petritis; Rui Zhao; Ronald J Moore; Samuel O Purvine; David G Camp; Richard D Smith
Journal:  J Proteome Res       Date:  2010-05-07       Impact factor: 4.466

7.  Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients.

Authors:  H Agersø; D F Brophy; H Pelzer; E J Martin; M Carr; U Hedner; M Ezban
Journal:  J Thromb Haemost       Date:  2011-02       Impact factor: 5.824

8.  Identification of the binding site for fondaparinux on Beta2-glycoprotein I.

Authors:  Alexey Kolyada; Alfredo De Biasio; Natalia Beglova
Journal:  Biochim Biophys Acta       Date:  2013-06-25

9.  Antithrombin: An anticoagulant, anti-inflammatory and antibacterial serpin.

Authors:  Alireza R Rezaie; Hemant Giri
Journal:  J Thromb Haemost       Date:  2020-03       Impact factor: 5.824

10.  Placental protein 5 (PP5) inhibits thrombin-induced coagulation of fibrinogen.

Authors:  A Meisser; P Bischof; H Bohn
Journal:  Arch Gynecol       Date:  1985
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.